Evidence map›Paper›PMID 38429762›Full record

ArticleEuropean journal of medical research2024

TR4 worsen urosepsis by regulating GSDMD.

Huan Wang, Shibin Zhu, Zhenwei Zhou, Zhenghui Wang, Wei Zhuang, Dingwei Xue, Zeyi Lu, Qiming Zheng, Lifeng Ding, Liangliang Ren and 6 more

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Huan Wang *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Shibin Zhu *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Zhenwei Zhou *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Zhenghui Wang *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Wei ZhuangDepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Dingwei XueDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Zeyi LuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Qiming ZhengDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Lifeng DingDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Liangliang RenDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Wenqing LuoDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Ruyue WangDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Guangju GeDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Liqun XiaDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Gonghui LiDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. 3193119@zju.edu.cn.
Haiyang WuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. 3203015@zju.edu.cn.
Zhejiang University · CNSir Run Run Shaw Hospital · CNSecond Affiliated Hospital of Fujian Medical University · CN

Funding

Key R & D plan of Zhejiang Province 2019C03089National Natural Science Foundation of China 81672520National Natural Science Foundation of China 81702504National Natural Science Foundation of China 81702508National Natural Science Foundation of China 81773789National Natural Science Foundation of China 81870484National Natural Science Foundation of China 82303202Zhejiang Province and Ministry 2020388200Zhejiang Provincial Natural Science Foundation of China LQ19H050011Zhejiang Provincial Natural Science Foundation of China LY17H160020Zhejiang Provincial Natural Science Foundation of China LY23H050004
6 · The paper itself

Abstract

backgroundUrosepsis is a life-threatening organ disease in which pathogenic microorganisms in the urine enter the blood through the vessels, causing an imbalance in the immune response to infection. The aim of this study was to elucidate the role of testicular orphan receptor 4 (TR4) in urosepsis.

methodsThe role of TR4 in the progression and prognosis of urosepsis was confirmed by analyzing data from online databases and clinical human samples. To mimic urosepsis, we injected E. coli bacteria into the renal pelvis of mice to create a urosepsis model. Hematoxylin and eosin staining was used to observe histopathological changes in urosepsis. The effects of the upregulation or downregulation of TR4 on macrophage pyroptosis were verified in vitro. Chromatin immunoprecipitation assay was used to verify the effect of TR4 on Gasdermin D (GSDMD) transcription.

resultsTR4 was more highly expressed in the nonsurviving group than in the surviving group. Furthermore, overexpressing TR4 promoted inflammatory cytokine expression, and knocking down TR4 attenuated inflammatory cytokine expression. Mechanistically, TR4 promoted pyroptosis by regulating the expression of GSDMD in urosepsis. Furthermore, we also found that TR4 knockdown protected mice from urosepsis induced by the E. coli.

conclusionsTR4 functions as a key regulator of urosepsis by mediating pyroptosis, which regulates GSDMD expression. Targeting TR4 may be a potential strategy for urosepsis treatment.

Indexed as

Body FluidsSepsisAnimalsCytokinesEosine Yellowish-(YS)Escherichia coliGasderminsHumansMicePhosphate-Binding ProteinsReceptors, SteroidReceptors, Thyroid HormoneCytokinesEosine Yellowish-(YS)GasderminsGSDMD protein, humanNR2C2 protein, humanNr2c2 protein, mousePhosphate-Binding ProteinsReceptors, SteroidReceptors, Thyroid HormoneGSDMDPyroptosisTR4Urosepsis

Identifiers

PMID38429762
PMCPMC10908015
OpenAlexW4392388105

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.